Sarah B Gitto, PhD
Department: Pathology and Laboratory Medicine
Contact information
Stellar Chance Laboratories
411 Curie Blvd, Rm 413A
Philadelphia, PA 19104
411 Curie Blvd, Rm 413A
Philadelphia, PA 19104
Publications
Education:
B.S. (Molecular Biology and Microbiology)
University of Central Florida, 2011.
B.S. (Health Sciences, Pre-Clinical Track )
University of Central Florida, 2011.
M.S. (Biomedical Sciences)
University of Central Florida, 2014.
Ph.D. (Biomedical Sciences)
University of Central Florida, 2017.
M.S. (Translational Science)
University of Pennsylvania, 2022.
Permanent linkB.S. (Molecular Biology and Microbiology)
University of Central Florida, 2011.
B.S. (Health Sciences, Pre-Clinical Track )
University of Central Florida, 2011.
M.S. (Biomedical Sciences)
University of Central Florida, 2014.
Ph.D. (Biomedical Sciences)
University of Central Florida, 2017.
M.S. (Translational Science)
University of Pennsylvania, 2022.
Selected Publications
Gitto SB, Pantel AR, Maxwell K, Pryma DA, Farwell MD, O'Brien SR, Clark AS, McDonald ES: [18F]FlourThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer. Communications Medicine March 2025.Weeks JK, Pantel AR, Gitto SB, Liu F, Schubert EK, Pryma DA, Farwell MD, Mankoff DA, Mach RH, Simpkins F, Lin LL.: [18F]Fluorthanatrace PET in ovarian cancer: Comparison with [18F]FDG PET, lesion location, tumor grade, and breast cancer gene mutation status. Journal of Nuclear Medicine 66(1): 34-39, January 2025.
Gitto SB, Medvedev S, Anderson M, Simpkins F, Powell DJ: Anti-angiogenics enhance immune checkpoint inhibitor efficacy in ovarian cancer. Journal for ImmunoTherapy of Cancer 12, November 2024.
Gitto SB, Ihewulezi CN, Onecha V, Lee H, Suarez-Garcia D, Bosque J, Simpkins F, Bertolet A, Pryma DA: PARP-targeted theranostic radiopharmaceutical therapy for drug-resistant ovarian cancer. European Journal of Cancer 211: 114580, October 2024.
Riad A, Gitto SB, Mach RH: Lipid metabolism and synthesis pathway analysis of Sigma-2 Receptor and Progesterone Membrane Component 1 to develop novel cancer cell therapies. European Journal of Cancer 211: 114580, October 2024.
Babazada H, Martorano P, Lee H, Gitto SB, Ihewulezi CN, Samanta M, Batra V, Maris JM, Farwell MD, Pryma DA: PARP1-targeted alpha therapy enhances target expression. European Journal of Nuclear Medicine and Molecular Imaging 51: S465-S465, September 2024.
Onecha VV, Bosque J, Suarez-Garcia D, Gitto SB, Ihewulezi C, Lee H, Pryma DA, Bertolet A: Time-driven dosimetry tool for in-vitro RPT experiments. AAPM 66th Annual Meeting and Exhibition July 2024.
Onecha VV, Suarez-Garcia D, Gitto SB, Lee H, Ihewulezi CN, Pryma D, Bertolet A: Space-and time-heterogeneous dosimetry for in vivo targeted alpha therapy. Journal of Nuclear Medicine June 2024.
Gitto SB, Young A, Bleiweiss I, Clark A, McDonald E. : PET imaging of PARP expression as a biomarker of response to chemotherapy in breast cancer: A nonrandomized clinical trial. Cancer Research 84: PS05-02, May 2024.
Xu H*, Gitto SB*, Ho GY*, Medvedev S, Shield-Artin KL, Kim H, Beard S, Kinose Y, Wang X, Barker HE, Ratnayake G, Hwang WT, Australian Ovarian Cancer Study, Hansen RJ, Strouse B, Milutinovic S, Hassig C, Wakefield MJ, Vandenberg CJ, Scott CL, Simpkins F.: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience 27(7), May 2024 Notes: *Co-first author.